The source behind the claim that a new COVID-19 strain in the UK is 70% more transmissible, Dr. Erik Volz of Imperial College, admits that the model that produced that statistic is flawed and that it is “too early to tell” if the strain is more easily spread.
On Saturday, UK Prime Minister Boris Johnson announced extreme new measures just before the holidays due to the emergence of a new COVID-19 variant. Per Johnson, as well as the UK’s Chief Medical Officer Chris Whitty who also spoke at Saturday’s press conference, the new strain – nicknamed VUI-202012/01 – is around 70% more transmissible, but no evidence shows it to be any more severe or deadly than previous strains.
According to the BBC, Johnson’s assertion that the new variant “may be up to 70% more transmissible,” was based on the information discussed the day prior by the UK government’s New and Emerging Respiratory Virus Threats Advisory Group, or NERVTAG. Yet, as the BBC notes, this figureapparently comes from a single source, a 10 minute presentation delivered by Dr. Erik Volz of Imperial College given last Friday, the same day as the NERVTAG meeting.
Volz – a close colleague of the discredited Neil Ferguson – delivered the presentation to COVID-19 Genomics UK (COG-UK), a research consortium largely funded by the UK government and the Wellcome Trust and, in particular, the Wellcome Sanger Institute. The Wellcome Sanger Institute recently came under fire for “misusing” the DNA of Africans to develop a “gene chip without proper legal agreements” and an upcoming Unlimited Hangout report will detail the ties of the Wellcome Trust to the UK eugenics movement, the Bill and Melinda Gates Foundation and the Oxford-AstraZeneca COVID-19 vaccine. Notably, the Wellcome-funded scientist behind that vaccine candidate, Adrian Hill, was recently quoted by the Washington Post as saying that “We’re in the bizarre position of wanting COVID to stay, at least for a little while…But cases are declining.”The UK government, Google and other powerful stakeholders are positioned to profit from sales of that particular vaccine candidate.